← Eichor
Condition: Anti Cd20 Therapy Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Anti Cd20 Therapy

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)
Phase 2 · 18 location(s) · Stichting Hemato-Oncologie voor Volwassenen Nederland · NCT04523428A Multicenter Real-life Study of Disseminated Borreliosis Cases Occurring in Patients Receiving Anti-CD20 Treatment in F
Phase N/A · 1 location(s) · University Hospital, Strasbourg, France · NCT07343089A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compar
Phase 3 · 187 location(s) · BeOne Medicines · NCT06943872A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Immune Thrombocytopenia
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT05995054A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytop
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06094881DALY II Japan/MB-CART2019.1 for DLBCL
Phase 2 · 5 location(s) · Miltenyi Biomedicine GmbH · NCT07288879DALY II USA/ MB-CART2019.1 for DLBCL
Phase 2 · 32 location(s) · Miltenyi Biomedicine GmbH · NCT04792489Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
Phase 1/Phase 2 · 26 location(s) · Kite, A Gilead Company · NCT049898034SCAR-T Therapy Post CD19-targeted Immunotherapy
Phase 1/Phase 2 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT04430530A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
Phase 1 · 6 location(s) · Kite, A Gilead Company · NCT07304154Safety, Pharmacokinetics, Immunogenicity BCD-256-1 and Divozilimab in Subjects With Systemic Lupus Erythematosus
Phase 1 · 1 location(s) · Biocad · NCT07136389A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
Phase 1/Phase 2 · 15 location(s) · Shanghai AbelZeta Ltd. · NCT05800977A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsin
Phase 3 · 1 location(s) · University Hospital, Montpellier · NCT07189325A Phase 1 Study of ADI-001 in Rheumatoid Arthritis
Phase 1 · 1 location(s) · Adicet Therapeutics · NCT07100873CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
Phase 1/Phase 2 · 1 location(s) · Medical College of Wisconsin · NCT04186520A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous
Phase 1 · 6 location(s) · Shanghai Jiaolian Drug Research and Development Co., Ltd · NCT05668403A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
Phase 1 · 1 location(s) · RenJi Hospital · NCT06249438Treatment of Presymptomatic (Stage 1) Type 1 Diabetes Pediatric Patients With Treg Cell Preparations and Anti-CD20 Antib
Phase 2 · 9 location(s) · PolTREG S.A. · NCT06688331Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Mali
Phase 1 · 2 location(s) · Sumithira Vasu · NCT05418088
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.